Diligence memo · auto-generated · as of July 3, 2026
Tenjove NewHemp Biotech Co., Ltd.
Tenjove NewHemp Biotech Co., Ltd. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Tenjove NewHemp Biotech Co., Ltd. operates in Biotechnology, based in CHAOYANG DISTRICT, BEIJING.
Sub-sector tags: biotech.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Tenjove NewHemp Biotech Co., Ltd. has raised $20M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $20M on 2019-07-01.
Most recent recorded round closed around 2019-07-01.
Valuation (modeled)modeled
Provath models Tenjove NewHemp Biotech Co., Ltd. at approximately $794M (range $40M–$3.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.29× the median modeled value of Series B Biotechnology companies in 2019–2021 (118 peers) — value vs value, same stage and era. Within the normal band (129% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 7.0 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 68% of Biotechnology peers (4293 compared).
Modeled value ranks above 87% of those peers.
Closest niche peers: Pandion Therapeutics Holdco LLC, Ocular Therapeutix, Inc, Insilico Medicine Cayman TopCo, Purigen Biosystems, Inc., Lucira Health, Inc..
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.